ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL specific tyrosine kinase inhibitors (TKIs), such as Imatinib (IM), Nilotinib and Dasatinib, have improved the 10-years survival time in 80% CML patients2.